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Proliferation of HIV-1 in the infected host is characterized by a progressive loss of CD41 T lymphocytes and consequent
dysregulation of the immune system. Both direct and indirect mechanisms have been proposed. We show here that proteins
with molecular weights 35, 48, and 110 kDa on stimulated primary human T cells are recognized by neutralizing antibodies
against the V3 loop of HIV-1 gp120. Recognition is specific since it can be blocked by a recombinant HIV-1 gp120.
Furthermore, these V3 monoclonal antibodies, as well as sera from AIDS patients that recognized these V3-like proteins,
induced killing of HIV-1-infected as well as uninfected T cells. This killing was also inhibited by HIV-1 gp120 V3 peptides.
These results indicate that the V3 loop shares epitopes with proteins on stimulated T cells. This may be an additional
autoimmune mechanism contributing to CD41 T cell disappearance in AIDS. V3 antibodies have been proposed as potential
prophylactic agents. However, if such vaccines were based on certain epitopes, they might induce cross-reacting immune
responses with cellular proteins. Vaccine candidates should be evaluated for such potential effects. © 1998 Academic Press
The hallmark of HIV-1 progression is the loss of CD41
T cells (Fauci, 1993). However, the exact mechanisms by
which HIV-1 kills CD41 T cell remain unresolved. Direct
CD41 T cell killing by HIV-1 is one possibility (Yu et al.,
1994). A high turnover of HIV-1 was associated with
depletion of T cells (Ho et al., 1995; Wei et al., 1995) and
plasma HIV-1 RNA levels were shown to be a predictor
for AIDS progression (Mellors et al., 1996; O’Brien et al.,
1996). Indirect mechanisms such as apoptosis may in-
duce killing of T cells (Gougeon and Montagnier, 1993).
HIV-1 proteins, such as tat and gp120, induced apoptosis
(Li et al., 1995; Westendorp et al., 1995). Other mecha-
nisms such as cross-linking of CD4 proteins (Banda et
al., 1992), CD81 cytotoxic T lymphocyte attack of CD41 T
cells binding gp120 (Koenig et al., 1988), the presence of
a superantigen encoded by the virus (Berberian et al.,
1993), or participation of the immune system via autoim-
munity including molecular mimicry have been sug-
gested as playing a role in killing CD41 T cells (Levy,
1994). Molecular mimicry occurs when pathogens share
antigenic sites with normal host cells (Fujinami and Old-
stone, 1989). For example, monoclonal antibodies (mAb)
to viral proteins can bind host components (Srinivasappa
et al., 1986; a hepatitis B virus polymerase peptide that
shares six consecutive amino acids with rabbit myelin
basic protein led to autoimmune disease (Fujinami and
Oldstone, 1985).
Retroviral infections, including HIV-1, may induce
autoimmune responses by molecular mimicry. Sup-
portive evidence for this possibility includes the ho-
mology between HIV-1 proteins such as envelope with
IL-1, IL-2 receptor, MHC class I and II, Fas, and pro-
teins of normal astrocytes (reviewed by Silvestris et
al., 1995). The homology of regions of gag, tat, and nef
with human normal proteins has been described (re-
viewed by Silvestris et al., 1995). Previously, we iden-
tified proteins in the human brain containing epitopes
that resembled the V3 loop of HIV-1 gp120 (Trujillo et
al., 1993). Three prominent human brain proteins of 35,
55, and 110 kDa reacted with monoclonal antibodies
against the V3 loop. The V3 loop of gp120 is important
in AIDS pathogenesis and in potential therapy (Emini
et al., 1992). In this current work, we had two goals.
First, we sought to determine the expression, localiza-
tion, and regulation of V3-like proteins in normal hu-
man CD41 T lymphocytes. Second, we wanted to know
whether anti-V3 antibodies could kill uninfected T
cells, an important question since depletion of CD41 T
lymphocytes cells is a primary feature of AIDS.
RESULTS
Detection of HIV-1 gp120 V3-like protein in T cells
To determine whether T cell protein would react with
a V3 mAb, we used a Western blot (WB) analysis of the
lysate of an established T cell line, SupT1. The lysate
was tested against a panel of monoclonal and poly-
clonal anti-HIV-1 antibodies. Only the V3 mAbs (NEA
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9205, raised against amino acids 308 to 322, and NEA
9284, raised against amino acids 307 to 330) reacted
with two prominent proteins of approximately 35 and
110 kDa (Trujillo et al., 1996a). In addition, other less
prominent proteins reacted with the V3 mAb, including
one of 45 and one of 50 kDa. These experiments were
repeated five times and yielded identical results (data
not shown).
To confirm that T cells share a common epitope with
HIV-1 envelope protein, the uninfected SupT1 cell line,
the SupT1 cell line infected (Trujillo et al., 1996b) with the
HIV-1IIIb strain (AIDS Research and References Reagent
Program, National Institutes of Health, Bethesda, MD),
and the viral lysate of HIV-1IIIb were probed with V3 mAb
in a WB analysis. As shown in Fig. 1A, the V3 mAb
cross-reacted with normal T cell proteins as well as the
HIV-1 gp120. To determine whether the human T cell
proteins with molecular weights 35, 45, 50, and 110 kDa
were specific to the V3 loop, a blocking experiment using
recombinant gp120 from a baculovirus expression sys-
tem (ABT, Cambridge MA) was performed. As shown in
Fig. 1B, binding of the V3 mAb with the human T cell
proteins was blocked with 10 mg/ml of rgp120, consistent
with previous studies of human brain proteins (Trujillo et
al., 1993). Similarly, 10 mg/ml of rgp120 inhibited binding
of V3 mAb to gp120 in the viral lysate (data not shown).
As an internal control, 10 mg of bovine albumin/ml was
tested for nonspecific inhibition. V3 mAb was not
blocked by this protein. These experiments were re-
peated with lysates of other CD41 T lymphocyte cell
lines including H9; Jurkat; Hut78; Molt3; and Molt4
(American Type Culture Collection, Rockville, MD). All
yielded identical results (data not shown).
To determine whether V3 mAb would react with normal
human CD41 T lymphocytes, as well as T-cell lines, PBL
from a healthy HIV-1-negative blood donor were purified
with Lymphocyte Separation Medium (LSM) (Organon
Teknika, Durham, NC). The cells were enriched and
activated with PHA (Sigma, St. Louis MO) and a subset of
CD41 cells were collected by affinity chromatography
column (Biolex Lab Inc., Canada). As shown in Fig. 1B
(left), the V3 mAb reacted with the same 35- and 110-kDa
proteins in both the CD41 and the SupT1 lymphocytes.
Initially, the CD41 lymphocytes appeared to display only
one protein of 48 kDa recognized by the V3 mAb. How-
ever, additional experiments with CD41 lymphocytes
when the gel was run for a longer time revealed two
proteins of 45 and 50 kDa, as was seen on SupT1
lymphocytes. As an Ig isotype-negative control, a mouse
mAb that was upstream from the V3 loop (amino acids
476 to 486) corresponding to the C5 region of gp120 was
used. It did not recognize any T cell proteins, but did
recognize the HIV-1 gp120, confirming V3 loop specificity
(Fig. 1B, center). In data not shown, 10 mg/ml of rgp120
inhibited binding of C5 mAb to gp120 of the cell lysate.
Also confirming the specificity of the V3 loop was the
observation that binding between the human T cell pro-
teins and V3 mAb was completely blocked with 10 mg of
rgp120 (Fig. 1B, right).
Increased expression of V3-like proteins in activated
T cells
Interestingly, we found that V3 mAb reacted more
than 10-fold more (measured by densitometry) with
proteins isolated from a tumor T cell line (SupT1) than
with proteins from normal human CD41 T lympho-
cytes, despite standardization of the protein extracts
FIG. 1. Western blot analysis of CD41 T lymphocytes with anti-HIV-1 gp120 V3 loop antibody. (A) WB analysis of a SupT1 CD41 T lymphocyte cell
line, SupT1 infected with HIV-1IIIb, and HIV-1IIIb viral lysates that were probed with V3 mAb. The arrows indicate proteins of 35, 45, 50, and 110 kDa.
Binding between V3 mAb and T cell proteins was completely blocked with recombinant HIV-1 gp120. (B) WB analysis of normal CD41 T lymphocytes
probed with V3 mAb. Cell lysates of normal CD41 lymphocytes, SupT1 cells, and SupT1 infected with HIV-1IIIb were probed with V3 mAb. Arrows
indicate proteins of 35, 50, and 110 kDa. A control HIV-1 gp120 475–486 mAb did not recognize any T cell proteins, but did recognize the HIV-1 gp120
protein. Blocking experiments using rgp120 completely inhibited the binding between V3 mAb and T cell proteins.
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(Bio-Rad Protein Assay, Melville, NY). This may be
because tumor cell lines have high mitotic activity,
while lymphocytes in vivo are quiescent (Zack, 1995).
We then determined if activation of human T cells
altered the expression of the V3-like proteins. PBL
from a normal blood donor were obtained and divided
into two aliquots. One served as a control and the
other was activated with PHA for 24 h. CD41 T cells
were obtained by an affinity chromatography column
and cell lysates from control and activated cells were
fractionated by SDS–PAGE and analyzed by WB. As
shown in Fig. 2A, the binding of V3 mAb to human T
cell proteins was increased 10-fold as measured by
densitometry, 24 h postactivation. As a negative iso-
type antibody control, C5 mAb was also tested. Both
control and PHA-activated CD41 T cells yielded neg-
ative results. In addition, a subset of CD81 T lympho-
cytes were similarly analyzed. The CD81 T cells were
purified and activated, and the proteins fractionated
and analyzed by WB. The binding of V3 mAb to CD81
T cell proteins remained minimal despite PHA activa-
tion (Fig. 2B).
To confirm the upregulation of the V3-like proteins by
activation, CD41 T cells were combined with fluorescent
V3 mAb and analyzed with flow cytometry. As shown in
the top panel of Fig. 3, low V3 mAb binding was seen in
nonactivated cells. Importantly, after 24 h activation with
PHA, T cells expressed a dramatic increased in V3-like
proteins. When the C5 mAb antibody was used as an
isotype IgG-negative control, fluorescence was low and
a negligible increase was noted after activation (Fig. 3,
bottom panel). These data confirm that activation is spe-
cific and causes only expression of more V3-like proteins
on CD41 T cells.
Immunostaining of uninfected T cells by HIV-1 gp120
V3 antibodies
To determine the anatomic distribution of the T cell V3
epitope, SupT1 lymphocyte cells were immunostained
with fluorescent V3 mAb and analyzed by laser confocal
microscopy. Imaging of the immunolabeled cells re-
vealed V3-like epitopes in the cytoplasmic region and on
cell surfaces (Fig. 4A). When unfixed CD41 SupT1 cells
were labeled with V3 mAb without prior acetone treat-
ment, the immunolabeled V3 mAb was primarily seen on
the cell surface (Fig. 4B). Ig isotype (C5 mAb), used as a
control, produced no significant binding (Fig. 4C). SupT1
cells incubated with anti-mouse FITC secondary anti-
body were also not labeled (data not shown). We then
analyzed one sample from seven AIDS patients which
had reacted with V3-like proteins (Trujillo et al., 1996a).
Uninfected T cells incubated with serum from a HIV-1-
positive patient revealed cell surface and cytoplasmic
distribution of antigen (Fig. 4C). As a negative control,
serum from an HIV-1-negative individual was used; there
was no significant binding (data not shown). V3 mAb and
serum antibodies from the HIV-1-positive patient stained
similar regions of the T cells (Figs. 4A and 4D).
Killing of T cells by V3 antibody binding and
complement
These results indicate that the V3 loop of HIV-1 gp120
shares epitopes with T cells. We suggest that an immune
response to the V3 loop in HIV-1-positive patients could
generate cross-reactive antibodies that bind to CD41 T
cells. This interaction plus activation of complement
could kill infected or uninfected CD41 T cells. To deter-
mine if binding of the V3 mAb to T cell proteins could
FIG. 2. Western blot and flow cytometry analysis of normal CD41 T lymphocytes before and after PHA activation. (A) Cell lysates of activated and
nonactivated CD41 T lymphocytes were probed with V3 mAb. Arrows indicate proteins of 35, 50, and 110 kDa. An HIV-1 gp120 475–486 (C5) mAb was
used as a negative control. (B) CD81 T cells were purified, activated, fractionated, and analyzed by WB. The binding of V3 mAb to CD81 T cell proteins
remained minimal despite PHA activation.
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FIG. 3. Flow cytometric analysis of V3 mAb binding to the surface of normal CD41 T lymphocytes before and after PHA activation (top). The blue
color indicates the nonactivated CD41 T lymphocytes, which shows minimal binding of the V3 mAb to the cell surface. As shown by the red color,
24 h after PHA treatment a significant shift to the right was noted indicating much greater V3 mAb binding. When the C5 mAb antibody was used as
an isotype IgG-negative control (bottom), fluorescence was low and minimal increase was noted after PHA activation.
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elicit T cell killing, we studied CD41 SupT1 cells in a
complement-dependent cytotoxic assay. As shown in
Fig. 5A, V3 mAb plus complement killed 70% of the CD41
SupT1 cells. When serum from an HIV-1-infected patient
containing antibodies which recognized the V3-like pro-
teins in a WB analysis was used, 70% killing of unin-
fected T cells was also observed. As a positive antibody
control, anti-CD4 monoclonal antibodies, OKT4A (Ortho
Diagnostic Inc., Raritan, NJ), were used with complement
and 60% of CD41 cells were killed. As an isotype anti-
body-negative control, we used a C5 mAb plus comple-
ment. Only 10% killing was observed; when V3 mAb, C5
mAb, or complement alone was used we saw a back-
ground of 10% killing of CD41 T cells. Similarly, sera of an
FIG. 4. CD41 SupT1 T lymphocytes immunostained using mouse monoclonal antibodies against V3, isotype Ig control, C5, and sera from
HIV-1-positive and negative individuals. (A) Confocal micrographs of immunolabeled cells with V3 mAb reveal V3 fluorescence in the cytoplasmic
region and on cell surfaces. (B) Confocal micrographs of immunolabeled living cells without acetone fixation reveal that V3 is located primarily on
cell surfaces. (C) When used as an IgG isotype control, C5 mAb produced no labeling. (D) Cells incubated with HIV-11 serum reveal a surface and
cytoplasmic distribution of the V3 antibody. Bar, 20 mm. Inset bars, 5 mm.
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HIV-1-seronegative individual showed negative results
when repeated twice.
Following HIV-1 infection, viral envelope proteins can
become incorporated into T cell membranes (Robey et
al., 1985). Since this could enhance T cell killing by V3
mAb, we repeated the same experiment after infecting
the CD41 SupT1 cells (Trujillo et al., 1996b) with HIV-1IIIb
strain (Fig. 5B). Now V3 mAb plus complement induced
90% killing of CD41 T cells. This increase of CD41 killing
by V3 mAb may reflect HIV-1 V3 epitopes on T cell
membranes following incorporation of HIV-1 envelope.
This explanation is supported by the fact that the C5
mAb, which recognizes the amino acids 476 to 486 of
gp120, now induced 60% CD41 T cell killing (Fig. 5B).
When V3 mAb without complement or when complement
only was used, 10 to 15% killing was observed. Serum
from an HIV-1-infected patient and CD4 mAb induced
approximately 80% killing of CD41 T cells. Again, sera of
an HIV-1-seronegative individual showed only 10% kill-
ing. This experiment was repeated twice with similar
results. In addition, when fresh activated CD41 T cells
were used with V3 mAb plus complement, approximately
60% killing was observed (data not shown).
To exclude the possibility of human T cell killing that
might reflect the use of guinea pig complement, the
same complement-dependent cytotoxic assay was per-
formed in the presence of human complement. As shown
in Figs. 6A and 6B, V3 mAb plus human complement
killed approximately 65 and 70% of uninfected and HIV-
1-infected T cells, respectively. To further determine
whether this reactivity was specific to complement, in-
activation of human complement for 1 h at 55°C was
performed. The V3 mAb in the presence of inactivated
human complement did not induced killing (Fig. 6A). To
determine whether the killing of T cells by V3 mAb plus
human complement was specific to the V3 loop, a block-
ing experiment using HIV-1 V3 peptide was performed.
As shown in Figs. 6A and 6B, the cytotoxic effect of the
V3 mAb on the T-cells was blocked by 10 mg/ml of V3
peptide.
More significantly, we wanted to exclude the possibil-
ity that human HIV-1 antibodies may be directed against
other proteins besides the V3-like peptides. Thus we
again conducted a blocking experiment using V3 pep-
tide. As shown in Fig. 6A, there was an over 70% reduc-
tion of killing of uninfected T cells. Similarly, in Fig. 5B,
50% reduction of killing of HIV-1-infected T cells was
observed. When V3 mAb, C5 mAb, or complement alone
FIG. 5. Killing of CD41 SupT1 T lymphocytes by V3 mAb binding and guinea pig complement. (A) CD41 SupT1 T lymphocytes were incubated with
V3 mAb and resuspended in guinea pig serum complement. These experiments were repeated with V3 mAb alone, complement alone, and C5 mAb
plus complement. As a positive control, a CD4 monoclonal antibody, OKT4A, was used. Serum from an HIV-1-positive patient that recognized similar
proteins in WB analysis was analyzed as well as serum from a seronegative person. (B) The CD41 SupT1 T lymphocytes were infected by HIV-1IIIb,
and a complement lysis experiment was performed as indicated above.
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was used we observed a background of approximately
10% killing of both uninfected and HIV-1-infected T cells
(data not shown). Similarly, sera of an HIV-1-seronegative
individual showed only 10% killing (data not shown).
DISCUSSION
These experiments demonstrate that the V3 loop of
HIV-1 gp120 shares epitopes with two prominent T cell
proteins of approximately 35 and 110 kDa. Other less
prominent T cell proteins that reacted included one of 45
and one of 50 kDa. Importantly, T cell protein homology
appears to be specific to HIV-1 gp120 since these inter-
actions can be blocked by rgp120 and V3 peptides. Use
of antibodies against the V3 loop and C5 region further
suggest that T cell binding specificity is confined to the
V3 loop. Activation of normal CD41 T lymphocytes by
PHA upregulates these V3-like epitopes. We also
showed that V3 mAb plus complement induced killing of
CD41 T lymphocytes in an in vitro assay. Collectively,
these results suggest that HIV-1 V3 loop epitopes shared
with T cell proteins may contribute to the depletion of T
cells in AIDS.
The V3 loop has been a focus for AIDS research (Foley
and Korber, 1995). It is formed by a disulfide bridge
between Cys residues 301 and 336. Although most of the
amino acids of the V3 loop are variable among different
strains of HIV-1, a Gly-Pro-Gly-Arg sequence at the tip of
the loop is highly conserved among isolates derived from
Europe and North America (Foley and Korber, 1995).
Several studies have also demonstrated that the princi-
pal neutralizing domain (PND) of HIV-1 lies within the V3
loop (LaRosa et al., 1990; Javaherian et al., 1990). This
highly conserved tip also forms a binding site for anti-
bodies that can inhibit fusion of HIV-1 with cells and thus
block HIV-1 infection. The V3 loop has been identified as
a fusion domain (Freed et al., 1992) and an anti-V3 anti-
body can by itself prevent in vitro infection (Skinner et al.,
1988). Furthermore, an anti-V3 antibody was able to con-
vey protection in two chimpanzees given HIV-1 (Emini et
al., 1992).
Our findings suggest that autoimmunity may contrib-
ute to T cell depletion in AIDS patients. But if this mech-
anism exists, why don’t HIV-1 asymptomatic individuals
with anti-V3 antibodies inevitably have CD41 T cell de-
pletion? Perhaps, the extent of T cell killing depends on
how activated the T cells are and the nature of the
antibody. It has been shown that sera of AIDS patients
contained autoantibodies that reacted with stimulated
FIG. 6. Killing of CD41 SupT1 T lymphocytes by V3 mAb binding and human complement. (A) CD41 SupT1 T lymphocytes were incubated with V3
mAb and resuspended in human complement. As a negative control, the human complement was inactivated for 1 h at 55°C. Binding between V3
mAb as well as human HIV-1 antibodies with CD41 SupT1 T lymphocytes was blocked with a V3 peptide. These experiments were repeated with
V3 mAb alone, complement alone, or with serum from a seronegative person. (B) The CD41 SupT1 T lymphocytes were infected by HIV-1IIIb, and a
complement lysis experiment was performed as indicated above.
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CD41 T cells (Stricker et al., 1987). We observed upregu-
lation of V3-like epitopes in activated CD41 T lympho-
cytes. Nonactivated CD41 T lymphocytes only expressed
small amounts of the V3-like proteins. Then, the binding
of cross-reactive antibodies to CD41 T cells may be
minimal and have no pathologic consequences. Simi-
larly, we observed minimal binding between the V3 mAb
and CD81 T lymphocytes, also consistent with AIDS
pathogenesis. However, any mitogenic stimulus, such as
concomitant viral or bacterial infections, may activate
CD41 T cells. This activation, characteristic of late
stages of HIV-1 infection, may lead to upregulation of
V3-like epitopes. Then, it becomes more likely that cross-
reactive V3 antibodies target CD41 T cells and induce
killing. These findings may also be relevant to cell-me-
diated immunity. The V3 loop is a main epitope for cyto-
toxic T lymphocyte (CTL) responses (Takahashi et al.,
1992). Therefore, activated T cells may also become
targets for killing by CTL. This V3 loop cross-reactivity
with human cells is not unique to CD41 T cells. Indeed
our first observation of molecular mimicry was made in
human central nervous system cells, especially neurons
(Trujillo et al., 1993, 1996a).
Our data demonstrating molecular mimicry between
the V3 loop and CD41 T cells suggest that the presence
of neutralizing V3 antibodies may enhance the progres-
sion to AIDS by contributing to elimination of CD41 T
cells. Consistent with this hypothesis is the observation
that neutralizing antibodies are present in symptomatic
stages of AIDS-related complex and AIDS (Weiss et al.,
1985; Boucher et al., 1989).
These findings have two implications. First, cells
which have V3-like epitopes such as neurons and T cells
may be susceptible to cell damage and/or killing when
anti-V3 antibodies are elicited. This phenomenon is prob-
ably proportional to the extent of their own activation.
Second, these observations may have consequences for
selecting vaccination strategies. The V3 loop is the prin-
cipal neutralizing domain of HIV-1 and anti-V3 antibody
may prevent HIV-1 infection (Emini et al., 1992; Javahe-
rian et al., 1990; Skinner et al., 1988). However, our
finding of cross-reactivity between V3 mAb and human T
cell proteins suggests that some V3 antibodies might
also induce autoimmune disease. Envelope vaccine of
equine infectious anemia virus caused autoimmune side
effects (Wei et al., 1995) and immunotherapy with V3 mAb
in humans has generated autoimmune side effects (G.
Bratt et al., 1991, abstract 2147, presented at VIIth Int.
Conf. AIDS, Florence Italy; J. Hinkula et al., 1993, abstract
PO-A28-0674, presented at IXth Int. Conf. AIDS, Berlin
Germany). Furthermore, Hinkula et al., (1994) have
shown decreased CD41 T cell counts in some patients
receiving passive immunotherapy with V3 mAb. But ge-
netic modifications of HIV-1 vaccines that minimize mim-
icry epitopes, while preserving others which are useful,
should lead to more appropriate HIV-1 vaccines.
In summary, our results indicate that the V3 loop of
HIV-1 gp120 shares common epitopes with proteins on
human T cell surfaces. Both V3 mAb and sera of AIDS
patients induced killing of uninfected CD41 T cells. An
immune response against an immunodominant viral
epitope (such as the V3 loop) may cross-react with sur-
face components of normal T cells. This may be a mech-
anism which contributes to CD41 T depletion in AIDS.
further identification of V3-related T cell proteins will give
better insight into the pathogenesis of AIDS and lead to
optimal treatments and vaccines.
MATERIALS AND METHODS
Antibodies
Several monoclonal and polyclonal anti-HIV-1 antibod-
ies were used, including polyclonal rabbit anti-HIV-1
gp120 (American Bio-Technologies, Inc., Cambridge,
MA); monoclonal anti-gp120 V3 loop made from amino
acids 308 to 322 (mAb) (NEA-9205, NEN, Boston, MA);
monoclonal anti-gp120 V3 loop made from amino acids
307 to 330 (NEA-9284, NEN); anti-gp41 (NEA-9303), anti-
p24 (NEA-9306); and anti-gp120 C5 loop made from
amino acids 475 to 486 (NEA-9201). We also used sera
from 7 of 26 HIV-1-positive subjects which recognized
the V3-like proteins (Trujillo et al., 1996a). According to
the Centers for Disease Control Classification of HIV
infection the 7 HIV-1-positive subjects were classified as
CDC IV (CDC, 1993).
Virus and cells
SupT1 cells, a CD41 T cell line, were obtained from
the AIDS Research and References Reagent Program.
The H9, Jurkat, Hut78, Molt3, and Molt4 CD41 T cell lines
were obtained from the American Type Culture Collec-
tion. These CD41 T cell lines were maintained at 37°C in
RPMI 1640 medium containing 10% heat-inactivated fetal
bovine serum and 1% antibiotic. HTLV-IIIb isolate (HIV-
1IIIb) was obtained from the AIDS Research and Refer-
ences Reagent Program. Cell-free supernatant from
SupT1 cells persistently infected with HIV-1IIIb was fil-
tered through a 0.45-mm membrane and spun in an
ultracentrifuge at 20,000 g for 2 h with 20% sucrose in
phosphate-buffered saline. The virus pellet was lysed
and mixed with reduced sample bufffer. The mixture was
boiled for 2 min and fractionated electrophoretically on a
12.5% sodium dodecyl sulfate–polycrylamide gel (SDS–
PAGE). PBLs were obtained from a normal blood donor
and were separated using LSM (Organon Teknika,
Durham, NC). CD41 T lymphocytes were separated by
an affinity chromatography column (Biotex Laboratories
Inc., Alberta, Canada).
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Western blot (WB) analysis
Viral and T cell proteins were fractionated by SDS–PAGE
(Laemmli, 1970). Proteins were transferred passively to a
nitrocellulose membrane (0.22-mm pore size, Bio-Rad). Im-
munoblot analysis was performed as described previously
(Barin et al., 1985). In a WB analysis, lysates of a SupT1
CD41 T lymphocyte cell line, SupT1 infected with HIV-1IIIb
(Trujillo et al., 1996b), and HIV-1IIIb were probed with V3
mAb at a dilution of 1:500 (10 mg/ml). Cell lysates of normal
CD41 T lymphocytes, SupT1 cells, and SupT1 infected with
HIV-1IIIb were probed with V3 mAb at a dilution of 1:500 (10
mg/ml). A second mouse monoclonal antibody that was
upstream from the V3 loop corresponding to the C5 region
(amino acids 475 to 486) served as an additional control (10
mg). The immnoreactivity of V3 mAb and T cells was mea-
sured by densitometry of the nitrocellulose membrane (15-
100 Digital Imaging System; Sun Bio Science, Branford, CT).
Blocking experiments
The blocking experiment used recombinant HIV-1
gp120 from a baculovirus expression system (ABT Inc.,
Cambridge MA); 10 mg of gp120/ml was incubated with
V3 mAb at 1:500 dilution (10 mg/ml) for 1 h at 37°C. As an
internal control, bovine albumin, 10 mg/ml, was tested for
nonspecific inhibition. It was .95% pure as estimated by
analysis of Coomassie blue-stained SDS–PAGE under
reduced and nonreduced conditions. It was recognized
by monoclonal and polyclonal anti-gp120 antibodies and
bound CD4 in ELISA or FACS analyses.
Ten micrograms per milliliter of an HIV-1 gp120 V3 loop
peptide (C-N-T-R-K-R-I-R-I-Q-R-G-P-G-R-A-F-V-T-I-G-K) was
used for blocking experiments in the complement cyto-
toxic assay (Intracel Corp., Cambridge, MA).
T cell activation and flow cytometry analysis
Lymphocytes were incubated for 24 h at 37°C in RPMI
1640 medium containing 10% heat-inactivated fetal bo-
vine serum and 1% antibiotic, plus 10 mg/ml of PHA to
activate them. CD41T lymphocytes were separated by
an affinity chromatography column (Biotex Laboratories
Inc.). Cell lysates of activated and control CD41 T lym-
phocytes were probed with 10 mg/ml of V3 mAb; 10
mg/ml of C5 mAb was used as a negative control. The
immunoreactivity of V3 mAb and T cells was measured
by densitometry of the nitrocellulose membrane (15–100
Digital Imaging System; Sun Bio Science). For the flow
cytometric analysis, PBL were obtained as mentioned
previously, and cells were sorted by FACS analysis (Bec-
ton–Dickinson, San Jose, CA), which yielded 95 to 98%
CD41 T lymphocytes. The cells were divided into two
aliquots; one was maintained as a control and the other
was activated with PHA for 24 h. CD41 T lymphocytes
were incubated with 10 mg/ml V3 mAb and cells were
exposed to anti-mouse IgG-FITC. The C5 mAb and FITC
alone served as negative controls. Measurements were
analyzed using a Becton–Dickinson software program.
This program plots logarithmic fluorescent values
against cell number.
Indirect immunofluorescence, microscopy, and image
analysis
SupT1 cells were put on glass slides and fixed with
acetone for 10 min. The slide was blocked with 5% sheep
serum and 3% bovine serum albumin in PBS for 30 min at
37°C. First, antibodies V3 mAb of the isotype Ig control or
the C5 mAb were applied for 30 min at 37°C. Albumin in
PBS was used as a negative control. These antibodies
were followed by FITC ‘‘Isomer’’ conjugate goat IgG frac-
tion to mouse Ig F(ab’)2(Organon Teknika Corp., Durham,
NC) for 30 min at 37°C. Immunostained cells were briefly
washed in PBS, then sealed in microwell chambers, and
examined using a Sarastro 2000 confocal laser scanning
microscope (CLSM) (Molecular Dynamics, Sunnyvale
CA) fitted with a 25 mW argon-ion laser. The microscope
was configured for single channel fluorescent imaging
with 514 nm excitation, 535 nm primary beam splitter,
10% laser transmission, and 18 mW laser power. Images
were recorded in 1024 image size format. A 60X 1.4
numeric aperture objective was used.
Complement cytotoxic assay
This assay was performed as previously described
(Duerst et al., 1991). The SupT1 cell pellet (6 3 106) was
incubated with anti-V3 or anti-C5 loop HIV-1 monoclonal
antibodies. We also used serum from an HIV-1-positive
or HIV-1-negative individual (dilution 1:20) for 45 min at
4°C. Afterward the cell–antibody complex was washed
twice with 13 Dulbeccos’ phosphate-buffered saline
(PBS) (Life Technologies Inc. Grand Island, NY) and re-
suspended in guinea pig serum complement (dilution
1:1) (Sigma Chemical Co., St. Louis, MO) or human com-
plement (from a healthy HIV-1-negative blood donor) (for
20 min at 4°C. Then, the cell–antibody–complement
complex was incubated for 30 min at 37°C. Finally, the
complex was washed twice in 13 PBS and the cytotox-
icity index was determined by trypan blue exclusion (Life
Technologies Inc.).
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